Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $159.4 million.

  • Gyre Therapeutics' Liabilities and Shareholders Equity rose 2726.29% to $159.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $567.2 million, marking a year-over-year increase of 1702.19%. This contributed to the annual value of $125.4 million for FY2024, which is 760.86% up from last year.
  • Gyre Therapeutics' Liabilities and Shareholders Equity amounted to $159.4 million in Q3 2025, which was up 2726.29% from $152.6 million recorded in Q2 2025.
  • Gyre Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $159.4 million during Q3 2025, with a 5-year trough of $10.0 million in Q3 2023.
  • Its 5-year average for Liabilities and Shareholders Equity is $88.8 million, with a median of $101.8 million in 2021.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first crashed by 8513.43% in 2023, then soared by 115692.49% in 2024.
  • Gyre Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $55.7 million in 2021, then surged by 52.26% to $84.8 million in 2022, then surged by 37.5% to $116.5 million in 2023, then rose by 7.61% to $125.4 million in 2024, then increased by 27.09% to $159.4 million in 2025.
  • Its last three reported values are $159.4 million in Q3 2025, $152.6 million for Q2 2025, and $129.8 million during Q1 2025.